DDInter4 DDInter1658
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aripiprazole
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vasopressin
Abarelix {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Vasopressin
Abarelix may lead to a major life threatening interaction when taken with Iloperidone